Pneumabort-K+1B, <Fort Dodge>the most complete vaccine available for protection against abortogenic Rhino. Contains both the 1b and 1p strain to protect against equine rhino-pneumonitis and abortion in pregnant mares. Dosage for pregnant mares, 2 ml IM during the 5th, 7th and 9th month of pregnancy. Syringe and needle included with 1 dose size only.

American Livestock Supply, Inc. has taken great care in assembling this label information. But, due to the possibility of human error or manufacture label changes, American Livestock Supply, Inc. disclaims responsibility for use or misuse of this product. Before use, always read and follow the manufacturer's label on the physical product.

PNEUMABORT-K+1B. Equine Rhinopneumonitis Vaccine. Killed virus.

INDICATIONS: For vaccination of healthy horses as an aid in the prevention of respiratory diseases caused by the EHV 1p and EHV 1b viruses as well as for use in pregnant mares as an aid in the prevention of abortion due to EHV 1 infections.

COMPOSITION: Pneumabort-K+1b is a killed virus vaccine of EHV 1p and 1b (equine rhinopneumonitis virus) which has been chemically inactivated with formalin, and combined with a specially prepared oil adjuvant. Pneumabort-K+1b is grown and prepared on an equine cell line substrate.

GENERAL INFORMATION: A short duration of serviceable immunity occurs after herpesvirus 1 infection or vaccination. It is necessary to maintain as high a level of immunity as possible to aid in protection against upper respiratory tract infection, and spread of field strains of virus to pregnant mares. Pregnant mares require the highest possible level of protection against infection after the fifth month of pregnancy; this should be maintained throughout pregnancy. The vaccine is a killed virus preparation, and may be administered at any time to horses or mares that may be moved from the premises, or that may be exposed to infection.

ADMINISTRATION AND DOSAGE: For pregnant mares, aseptically administer one 2 mL dose intramuscularly during the 5th, 7th and 9th months of pregnancy. Revaccinate annually at the 5th, 7th and 9th months of pregnancy. For young horses, administer one 2 mL dose intramuscularly followed by a second 2 mL dose 3 to 4 weeks later. Revaccinate annually at the 5th, 7th and 9th months of pregnancy. For young horses, administer one 2 mL dose intramuscularly followed by a second 2 mL dose 3 to 4 weeks later. Revaccinate with a single 2 mL dose 6 months after the second primary dose and annually thereafter. To insure proper placement and retention of the vaccine, inject deep into the heavy muscles of the hindquarter. Mild exercise to promote absorption is recommended for one week after injection. Maiden and barren mares kept in barn- or pasture-contact with vaccinated pregnant mares should be vaccinated on the same schedule as the pregnant mares with which they are in contact. Mares more than five months pregnant at the time of arrival on a farm should be vaccinated upon arrival and at two-month intervals until foaling. Pregnant mares that are in contact with mares that have aborted equine herpesvirus 1 infected fetuses should be vaccinated. Such vaccination may provide immunity for those mares in the group which are not incubating an abortigenic infection at the time of vaccination.

CAUTION: Store in dark at 2 to 7 degrees C (35 to 45 degrees F). Avoid freezing. Shake vigorously to assure uniform suspension of the vaccine. There is no seal on the 10 dose vial. When used according to instructions, local or systemic reactions rarely occur. An occasional local swelling or induration at the site of injection may be encountered. Do not vaccinate within 60 days before slaughter. In case of anaphylactoid reaction, administer epinephrine. Thimerosal, neomycin, polymyxin B and amphotericin B added as preservatives. For veterinary use only.

SAME COVERAGE AS: Prodigy, item # PRODIGY02.